Cervical Cancer Screening — Coverage Criteria and Reimbursement Guidance
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage criteria and reimbursement guidance for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix, including age- and risk-based limitations and applicable procedure codes.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cervical Cancer Screening
Screening for immunocompromised individuals
Covered when ANY of the following are met for immunocompromised or immunosuppressed individuals:
Policy: immunocompromised or immunosuppressed individuals meet coverage criteria for annual cytology.
Specified in policy for immunocompromised individuals aged 30+.
Screening ages 21-29
Covered when ALL of the following are met:
Policy states annual Pap meets coverage criteria for ages 21–29.
Screening ages 30-65
Covered when ANY one of the following is met:
Policy lists three acceptable annual options for ages 30–65.
HPV positive / cytology negative
Covered when the following is met:
Policy explicitly supports HPV-16 and HPV-18 nucleic acid testing in this scenario.
Cessation of routine screening (>65)
Routine screening not covered when ALL of the following are met:
Policy defines adequate screening history required to stop routine screening.
Post-hysterectomy
Not covered when the following are met:
Explicit exclusion in policy for post-hysterectomy individuals without prior cervical disease.
The policy explicitly states that the inclusion of low-risk strains of HPV in co-testing and similar technologies DO NOT MEET COVERAGE CRITERIA due to lack of supporting evidence. Providers should not submit or expect coverage for tests or panels that report only low-risk HPV types as part of cervical cancer screening.
Within the reference entries cited by this policy, there are no additional explicit exclusions listed beyond those identified in the reimbursement policy. Consult the primary reimbursement criteria for stated exclusions.
Cervical cancer screening for individuals less than 21 years of age DOES NOT MEET COVERAGE CRITERIA. Screening in this age group is not covered except as addressed by other specific clinical indications documented elsewhere in the member’s record.
The reference lists used to inform this policy do not include explicit statements labeled as “not medically necessary” beyond the coverage determinations provided in the reimbursement policy language; interpretive determinations are found in the policy criteria themselves.
Applicable Procedure Codes and Coding Guidance
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44). |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed. |
| 88141 | Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician. |
| 88142 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision. |
| 88143 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision. |
| 88147 | Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision. |
| 88148 | Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision. |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision. |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer- assisted rescreening under physician supervision. |
Provider Actions, Documentation & Authorization
Verify member benefits
Verify member benefits — Coverage depends on age, risk status, and prior screening history; verify member benefits at time of request.
- Age under 21: Screening for individuals less than 21 years of age does not meet coverage criteria and may be denied.
- Older than 65 with adequate history: Routine screening for individuals over 65 who are not high-risk with an adequate screening history does not meet coverage.
- Post-hysterectomy without history: Cervical cancer screening after hysterectomy when there is no history of cervical cancer or pre-cancer does not meet coverage.
Prior authorization
Prior authorization — No prior authorization requirements are specified in these reference citations.
Step therapy / Alternative testing
Step therapy / Alternative testing — No step therapy requirements specified; inclusion of low-risk HPV strains in co-testing and other alternative screening technologies are listed as not meeting coverage criteria.
- Inclusion of low-risk HPV strains in co-testing is not covered.
- Other technologies for cervical cancer screening (alternative/experimental methods) are not covered due to insufficient evidence.
Step therapy
Step therapy — No step therapy requirements are referenced in these citations.
Supporting clinical documentation
Supporting clinical documentation — Document age, immunocompromised/high-risk status, prior screening results and dates to support coverage.
- Include date and result of prior Pap smears and/or HPV tests.
- Document immunocompromised status (e.g., organ transplant, HIV) or in utero DES exposure when applicable.
Documentation/submission requirements
Documentation/submission requirements — No specific documentation or submission forms are specified in these reference citations; however, supporting clinical documentation as above should be provided when requesting coverage.
- No payer-specified submission forms are listed in references.
- Provide pertinent clinical records and test results to support medical necessity when requested.
Age under 21
Age under 21 — Screening for individuals less than 21 years of age does not meet coverage criteria and may be denied.
Provider denial triggers
Provider denial triggers — None specified in these reference lists; no explicit denial triggers are described in these citations beyond the coverage criteria noted above (age, risk status, prior screening history).
Background
Cervical cancer screening is intended to detect precancerous lesions and invasive cancer using a combination of methods: Papanicolaou (Pap) cytology, high-risk HPV testing, and colposcopy when indicated. The policy supports age- and risk-based use of these modalities, including annual Pap testing for ages 21–29, multiple acceptable screening options for ages 30–65 (Pap, high-risk HPV testing, or co-testing), targeted testing for individuals who are HPV positive but cytology negative (HPV-16/18 genotyping), and modified recommendations for immunocompromised individuals and those over 65 with adequate prior screening.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.